Acquisition by Darrell Lea of 100000 shares of Cellectar Biosciences at 1.68 subject to Rule 16b-3
CLRB Stock | USD 0.30 0.98 76.27% |
About 52% of Cellectar Biosciences' investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Cellectar Biosciences suggests that some traders are interested. The current market sentiment, together with Cellectar Biosciences' historical and current headlines, can help investors time the market. In addition, many technical investors use Cellectar Biosciences stock news signals to limit their universe of possible portfolio assets.
Cellectar |
Filed transaction by Cellectar Biosciences Officer Chief Commercial Officer. Grant, award or other acquisition pursuant to Rule 16b-3
Read at macroaxis.com
Cash Flow Correlation
Cellectar Biosciences' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Cellectar Biosciences' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.Click cells to compare fundamentals
Cellectar Biosciences Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Cellectar Biosciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Cellectar Biosciences Fundamental Analysis
We analyze Cellectar Biosciences' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cellectar Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cellectar Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Return On Equity
Return On Equity Comparative Analysis
Cellectar Biosciences is currently under evaluation in return on equity category among its peers. Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Cellectar Biosciences Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Cellectar Biosciences stock to make a market-neutral strategy. Peer analysis of Cellectar Biosciences could also be used in its relative valuation, which is a method of valuing Cellectar Biosciences by comparing valuation metrics with similar companies.
Peers
Cellectar Biosciences Related Equities
BNTC | Benitec Biopharma | 11.41 | ||||
NXTC | NextCure | 4.42 | ||||
MNPR | Monopar Therapeutics | 2.60 | ||||
ALRN | Aileron Therapeutics | 2.34 | ||||
TENX | Tenax Therapeutics | 1.18 | ||||
LUMO | Lumos Pharma | 0.23 | ||||
PULM | Pulmatrix | 0.67 | ||||
BOLT | Bolt Biotherapeutics | 2.37 | ||||
BPTH | Bio Path | 3.38 | ||||
CAPR | Capricor Therapeutics | 4.17 |
Complementary Tools for Cellectar Stock analysis
When running Cellectar Biosciences' price analysis, check to measure Cellectar Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cellectar Biosciences is operating at the current time. Most of Cellectar Biosciences' value examination focuses on studying past and present price action to predict the probability of Cellectar Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cellectar Biosciences' price. Additionally, you may evaluate how the addition of Cellectar Biosciences to your portfolios can decrease your overall portfolio volatility.
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |